Back to all webinars
Expert review of EHA and ICML 2023: Actionable insights for CLL and indolent lymphomas
Carol Moreno and Pier Luigi Zinzani share their highlights from two of the biggest annual events in hematology, focusing on developments that will shape the future of clinical practice in CLL and indolent lymphomas.
Speakers
Practice-changing data in CLL
Fast-forward to:
Fixed-duration ibrutinib + venetoclax
6501b513e3ec72058294dea5
MURANO study: VenR vs. BR in patients with R/R CLL
6501c2cc860023057552a936
Zanubrutinib in CLL
6501c3c9eab82d0573abcae1
Practice-changing data in indolent lymphomas
Fast-forward to:
EPCORE™ NHL-2 study: Epcoritamab plus rituximab and lenalidomide
6501c538eab82d0573abcaf7
TRANSCEND FL study: Lisocabtagene maraleucel
6501c66de3ec72058294defc
ROSEWOOD study: Zanubrutinib plus obinutuzumab vs. obinutuzumab
6501c786860023057552a987
Panel discussion and audience Q&A
Fast-forward to:
In general, do you prefer a bispecific antibody or CAR-T cell therapy approach? Is there a preferred sequence?
6501cb36eab82d0573abcb40
For what patient profile would you consider doublet therapy (BTKi + BCL2i) for relapsed CLL?
6501cbbf8a7d5f057442093a
Are we close to seeing MRD-guided treatment being used for CLL in clinical practice?
6501cc278a7d5f0574420943
How would you treat a patient with CLL if they experienced disease progression while receiving first-line treatment with a BTK inhibitor?
6501cc93e3ec72058294df6e
What treatment would you recommend for patients with CLL following first-line therapy with a BCL2 and BTK inhibitor?
6501cd918a7d5f0574420962
Summary
No entries